JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Pracoviště: University Hospital Basel University of Basel B...

4 záznamů v Medvik Filtry

Článek

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Healey, Jeff S
Autor Healey, Jeff S ORCID From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Lopes, Renato D
Autor Lopes, Renato D From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Granger, Christopher B
Autor Granger, Christopher B From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Alings, Marco
Autor Alings, Marco From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Rivard, Lena
Autor Rivard, Lena From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
McIntyre, William F
Autor McIntyre, William F From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Atar, Dan
Autor Atar, Dan From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Birnie, David H
Autor Birnie, David H From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Boriani, Giuseppe
Autor Boriani, Giuseppe From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)
Camm, A John
Autor Camm, A John From the Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., W.F.M., D.C., J.A.W., L.X., K.S., S.N., R.M., S.J.C.), the Montreal Heart Institute, University of Montreal, Montreal (L.R.), the University of Ottawa Heart Institute, Ottawa (D.H.B.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, QC (F.P.), the Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, AB (S.B.C.), and the Université de Sherbrooke, Sherbrooke, QC (F.A.-P.) - all in Canada the Duke Clinical Research Institute, Duke University, Durham, NC (R.D.L., C.B.G.) Amphia Ziekenhuis, Breda, the Netherlands (M.A.) Oslo University Hospital and the University of Oslo, Oslo (D.A.) the University of Modena and Reggio Emilia, Modena (G.B.), and the Department of Clinical Sciences and Community Health, University of Milan, and the Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan (M. Proietti) - all in Italy St. George's, University of London, London (A.J.C.), and Liverpool Heart and Chest Hospital, Liverpool (D.J.W.) - both in the United Kingdom J.W. Goethe University, University Hospital Department of Cardiology, Frankfurt, Germany (J.W.E., S.H.H.) the Medical University of South Carolina, Charleston (M.R.G.) Michigan State University, Lansing (J.I.) the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (J.K.) the University of Rochester, Rochester, NY (V.K.) Semmelweis University, Budapest, Hungary (V.K.) Karolinska Institutet and the Heart, Vascular, and Neurology Theme, Karolinska University Hospital, Stockholm (C.L.) the University of Rennes, Rennes, France (P.M.) Cliniques du Sud-Luxembourg, Arlon, Belgium (G.M.) Hospital Universitario La Luz, Madrid (J.B.M.), and Hospital Costa del Sol, Marbella (M. Pombo) - both in Spain Aarhus University Hospital and Aarhus University, Aarhus, Denmark (J.C.N.) University Hospital Basel, University of Basel, Basel, Switzerland (C.S.) the Veterans Affairs Portland Health Care System, Portland, OR (I.G.Z.) and Abrazo Arrowhead Hospital, Glendale, AZ (A.K.)

The New England journal of medicine. 2024 ; 390 (2) : 107-117. [pub] 20231112

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit. METHODS: We conducted a trial involving patients with subclinical atrial fibrillation lasting 6 minutes to 24 hours. Patients were randomly assigned in a double-blind, double-dummy design to receive apixaban at a dose of 5 mg twice daily (2.5 mg twice daily when indicated) or aspirin at a dose of 81 mg daily. The trial medication was discontinued and anticoagulation started if subclinical atrial fibrillation lasting more than 24 hours or clinical atrial fibrillation developed. The primary efficacy outcome, stroke or systemic embolism, was assessed in the intention-to-treat population (all the patients who had undergone randomization); the primary safety outcome, major bleeding, was assessed in the on-treatment population (all the patients who had undergone randomization and received at least one dose of the assigned trial drug, with follow-up censored 5 days after permanent discontinuation of trial medication for any reason). RESULTS: We included 4012 patients with a mean (±SD) age of 76.8±7.6 years and a mean CHA2DS2-VASc score of 3.9±1.1 (scores range from 0 to 9, with higher scores indicating a higher risk of stroke); 36.1% of the patients were women. After a mean follow-up of 3.5±1.8 years, stroke or systemic embolism occurred in 55 patients in the apixaban group (0.78% per patient-year) and in 86 patients in the aspirin group (1.24% per patient-year) (hazard ratio, 0.63; 95% confidence interval [CI], 0.45 to 0.88; P = 0.007). In the on-treatment population, the rate of major bleeding was 1.71% per patient-year in the apixaban group and 0.94% per patient-year in the aspirin group (hazard ratio, 1.80; 95% CI, 1.26 to 2.57; P = 0.001). Fatal bleeding occurred in 5 patients in the apixaban group and 8 patients in the aspirin group. CONCLUSIONS: Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).

MeSH
antikoagulancia * škodlivé účinky terapeutické užití MeSH
Aspirin * škodlivé účinky terapeutické užití MeSH
cévní mozková příhoda * etiologie prevence a kontrola MeSH
dvojitá slepá metoda MeSH
embolie * etiologie prevence a kontrola MeSH
fibrilace síní * komplikace diagnóza MeSH
inhibitory faktoru Xa škodlivé účinky terapeutické užití MeSH
krvácení chemicky indukované MeSH
lidé MeSH
pyridony škodlivé účinky MeSH
senioři nad 80 let MeSH
senioři MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři nad 80 let MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
randomizované kontrolované studie MeSH
srovnávací studie MeSH
Geografické názvy
Kanada MeSH

Článek

Four-year mortality in women and men after transfemoral transcatheter aortic valve implantation using the SAPIEN 3

Catheterization and cardiovascular interventions. 2021 ; 97 (5) : 876-884. [pub] 20200904

Catheter Cardiovasc Interv
ISSN 1522-726X
Medvik
Zdroj

OBJECTIVES: To investigate 4-year, post-transcatheter aortic valve implantation (TAVI) survival and predictors of survival by sex, in a real-world cohort that underwent transfemoral TAVI with SAPIEN 3 transcatheter heart valve. BACKGROUND: Previous TAVI investigations of first-generation devices demonstrated an early- to mid-term survival advantage in women compared with men. METHODS: SOURCE 3 (SAPIEN 3 Aortic Bioprosthesis European Outcome) is a post-approval, multicentre, observational registry. Patients (N = 1,694, 49.2% women, age 81.7 ± 6.7 years) with severe aortic stenosis and high surgical risk (logistic EuroSCORE 17.8%) underwent TAVI between 2014 and 2015. Kaplan-Meier event estimates were used to determine mortality by sex. Predictors of overall mortality were identified using a cox multivariate proportional hazard model. RESULTS: At 4 years, women had lower all-cause mortality than men (36.0 vs 39.7%; p = .0911; HR: 0.87 [95% CI: 0.75-1.02]). No difference was observed for cardiac mortality between women 24.2% and men 24.7% (p = .76; HR: 0.97 [95% CI: 0.79-1.19]). When adjusted for baseline characteristics (age, height, weight, NYHA functional class, renal insufficiency, EuroScore, and tricuspid regurgitation), sex had no impact on mortality. CONCLUSIONS: In this large, real-world cohort, all-cause mortality trended lower in women than men at 4 years post TAVI; however, several baseline factors, but not sex, were predictors of mortality. No difference between sexes was observed for cardiovascular mortality.

MeSH
aortální chlopeň diagnostické zobrazování chirurgie MeSH
aortální stenóza * diagnostické zobrazování chirurgie MeSH
lidé MeSH
registrace MeSH
rizikové faktory MeSH
srdeční chlopně umělé * MeSH
transkatetrální implantace aortální chlopně * škodlivé účinky MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH

Článek

Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study

European journal of heart failure. 2020 ; 22 (2) : 303-312. [pub] 20191209

Eur J Heart Fail
ISSN 1879-0844
Medvik
Zdroj

AIMS: Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM-HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER-HF and TRANSITION). However, data are lacking for the initiation of sacubitril/valsartan in newly diagnosed (de novo) HFrEF. Here, we assess the tolerability of initiating sacubitril/valsartan following ADHF in TRANSITION subgroups of patients with a de novo vs. prior diagnosis of HFrEF. METHODS AND RESULTS: TRANSITION randomised 1002 patients to pre- and post-discharge initiation of sacubitril/valsartan (analysis set n = 991, following exclusions for mis-randomisation). In this post-hoc analysis, tolerability to sacubitril/valsartan [proportion of patients achieving target dose (97/103 mg b.i.d.) at 10 weeks post-randomisation], adverse events (AEs) and serious AEs (SAEs) were compared in de novo (n = 286) and prior HFrEF (n = 705) subgroups. More de novo than prior HFrEF patients achieved target dose at Week 10 (56% vs. 45%; relative risk ratio 1.30, 95% confidence interval 1.12-1.52, P < 0.001), and fewer had SAEs and permanent treatment discontinuations. Initiation of sacubitril/valsartan did not prevent the concomitant initiation and up-titration of guideline-directed HF therapies. De novo patients showed faster and greater decreases in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin-T, and lower rates of HF and all-cause rehospitalisation vs. prior HFrEF. CONCLUSIONS: After ADHF, first-line initiation of sacubitril/valsartan in de novo HFrEF, alongside the initiation of other guideline-directed therapies, is feasible and is associated with a better risk-benefit profile than in patients with prior HFrEF. Early intervention with sacubitril/valsartan may be considered to delay disease progression in patients with de novo HFrEF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02661217.

MeSH
aminobutyráty terapeutické užití MeSH
bifenylové sloučeniny terapeutické užití MeSH
fixní kombinace léků MeSH
lidé MeSH
následná péče MeSH
propuštění pacienta MeSH
srdeční selhání * farmakoterapie MeSH
valsartan terapeutické užití MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
randomizované kontrolované studie MeSH

Článek

Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study

European journal of heart failure. 2019 ; 21 (8) : 998-1007. [pub] 20190527

Eur J Heart Fail
ISSN 1879-0844
Medvik
Zdroj

AIMS: To assess tolerability and optimal time point for initiation of sacubitril/valsartan in patients stabilised after acute heart failure (AHF). METHODS AND RESULTS: TRANSITION was a randomised, multicentre, open-label study comparing two treatment initiation modalities of sacubitril/valsartan. Patients aged ≥ 18 years, hospitalised for AHF were stratified according to pre-admission use of renin-angiotensin-aldosterone system inhibitors and randomised (n = 1002) after stabilisation to initiate sacubitril/valsartan either ≥ 12-h pre-discharge or between Days 1-14 post-discharge. Starting dose (as per label) was 24/26 mg or 49/51 mg bid with up- or down-titration based on tolerability. The primary endpoint was the proportion of patients attaining 97/103 mg bid target dose after 10 weeks. Median time of first dose of sacubitril/valsartan from the day of discharge was Day -1 and Day +1 in the pre-discharge group and the post-discharge group, respectively. Comparable proportions of patients in the pre- and post-discharge initiation groups met the primary endpoint [45.4% vs. 50.7%; risk ratio (RR) 0.90; 95% confidence interval (CI) 0.79-1.02]. The proportion of patients who achieved and maintained for ≥ 2 weeks leading to Week 10, either 49/51 or 97/103 mg bid was 62.1% vs. 68.5% (RR 0.91; 95% CI 0.83-0.99); or any dose was 86.0% vs. 89.6% (RR 0.96; 95% CI 0.92-1.01). Discontinuation due to adverse events occurred in 7.3% vs. 4.9% of patients (RR 1.49; 95% CI 0.90-2.46). CONCLUSIONS: Initiation of sacubitril/valsartan in a wide range of heart failure with reduced ejection fraction patients stabilised after an AHF event, either in hospital or shortly after discharge, is feasible with about half of the patients achieving target dose within 10 weeks. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT02661217.

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH